RAY B Stock Overview
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide.
No risks detected for RAY B from our risk checks.
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||kr46.25|
|52 Week High||kr74.80|
|52 Week Low||kr40.00|
|1 Month Change||-3.95%|
|3 Month Change||-21.21%|
|1 Year Change||-22.79%|
|3 Year Change||-72.49%|
|5 Year Change||-73.72%|
|Change since IPO||8,061.86%|
Recent News & Updates
|RAY B||SE Healthcare Services||SE Market|
Return vs Industry: RAY B exceeded the Swedish Healthcare Services industry which returned -34.6% over the past year.
Return vs Market: RAY B exceeded the Swedish Market which returned -27.6% over the past year.
|RAY B volatility|
|RAY B Average Weekly Movement||7.9%|
|Healthcare Services Industry Average Movement||7.4%|
|Market Average Movement||6.9%|
|10% most volatile stocks in SE Market||11.6%|
|10% least volatile stocks in SE Market||4.3%|
Stable Share Price: RAY B is not significantly more volatile than the rest of Swedish stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: RAY B's weekly volatility (8%) has been stable over the past year.
About the Company
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment worldwide. It develops and markets RayStation, a treatment planning system for treatment activities, such as automated planning, adaptive therapy, multi-criteria optimization, fast and accurate dose computations, OAR dose reduction, robustness, machine learning, VMAT, IMRT, 3D-CRT, virtual simulation, electron beam therapy, tomotherapy, stereotactic, proton therapy, carbon ion therapy, and boron neutron capture therapy. The company also develops RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information system to support cancer treatment activities.
RaySearch Laboratories AB (publ) Fundamentals Summary
|RAY B fundamental statistics|
Is RAY B overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|RAY B income statement (TTM)|
|Cost of Revenue||kr44.49m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Nov 17, 2022
|Earnings per share (EPS)||-1.12|
|Net Profit Margin||-5.54%|
How did RAY B perform over the long term?See historical performance and comparison